Don't Miss

International Conference to Discuss the Outbreaks of Whooping Cough

By on September 7, 2013

There are surges every year in the number of people being affected by the whooping cough. The health condition of the patients suffering from whooping cough is considered to be highly infectious and dangerous health. This is the reason that the official committees have decided to focus about whooping cough 10th International Symposium on Bordetella that is to be held from Sunday 8th to 11th of September, 2013 in the Trinity Biomedical Sciences Institute, Trinity College Dublin.

International Conference to Discuss the Outbreaks of Whooping CoughThe deadly whooping cough is a disease also known as pertussis and is considered highly infectious caused mainly because of the Bordetella bacteria. This disease is increasing in various developed countries such as Ireland. In the year 1940 there was a whole bacteria vaccine introduced in order to control the whooping cough eventually.

But there are side effects generated by the constant use of pertussis vaccination, which had led to the research and development of a vaccine that is manufactured from a distinct variety of bacteria components extensively. Acellular pertussis vaccine is the new name given for the presently introduced vaccine to treat whooping cough in a more clear way without any side effects.

This has been proved to be safe for little children and infants, thus effectively controlling this dreadful disease. In recent times death rates of adults and adolescent children affected with whooping cough has risen significantly. More than 41,000 cases were deducted in the US and UK saw over 10,000 infants and adults whooping cough death.

This constant death may relate to the failure of protective immunity provided by the vaccination quicker period of time, which might increase the necessity for booster vaccinations to be done more frequently. The Professor of Experimental Immunology, Kingston Mills, in the School of Biochemistry and Immunology at Trinity College, has organized the international symposium, in which scientists who are performing immunology, pathogenesis and genetics research for B, pertussis.

Also physicians like the US Centre for Disease Control (CDC), government health agencies and chief vaccine manufacturing pharmaceutical companies representatives, who works on clinical and epidemiology aspects are expected to be present in the symposium to discuss. Professor Mills announced to the reporters that the issues regarding increase death rates in infants and adults because of the fatal disease – the whooping cough and to find a permanent vaccination solution.

He added, “This meeting will provide an ideal forum for scientists, clinicians, healthcare officials and industry to discuss the recent outbreaks of whooping cough and how research in basic science may help to provide a better vaccine. It is a great honor to have been asked to organize this major meeting at Trinity College and a great opportunity for us to showcase Irish researchers’ involvement in an area of international medical importance.”

Professor Kingston Mills along with his School of Biochemistry and Immunology  research team discovered that the current vaccination against whooping coughs can be base and help in finding a new improved vaccination for whooping cough. According to the research it was found that most of the vaccines comprises of a particular adjuvant that boosts a human body’s immune system in order to respond against the viral or bacterial antigen present in the vaccine. This acellular pertussis vaccine medicine contains alum which is basically an aluminum salt. The scientists however thinks that the vaccine could be more effective and improved if different adjuvant is used.

Most vaccines include a component called an adjuvant to boost immune responses to the bacterial or viral antigens in the vaccine and the acellular pertussis vaccine uses aluminium salt, called alum. However, the research team has confronted their hope to discover a more promising vaccine that could be improved further by using a different adjuvant.

About Rekha